and Michael Holers, MD, answer audience questions at the end of the 2026 Transforming Healthcare event
In terms of weight loss, there was no significant difference between weight loss with EX (-3.6 kg) and with EX-LAR (-3.7 kg) (115)
Mojsov as the 2026 Kimberly Prize winner for her pioneering discoveries and contributions on GLP-1
Below I break down what this regulatory shift means for Novo Nordisks revenue trajectory, margin profile, and valuation and why it materially strengthens the WeightWatchers thesis as well.
Hypoglycemia: While GLP-1 medications themselves rarely cause hypoglycemia (low blood sugar) when used as monotherapy, combining them with a mechanism of action that causes hypoglycemia such as insulin or sulfonylureas can increase the risk of hypoglycemia
Popoviciu MS, Pduraru L, Yahya G, Metwally K, Cavalu S